SCHEMBL5787351

SCHEMBL5787351

COc1cc(CC(C)N)cc2c1OC(C)(C)C2

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.40
HTR2A P28223 1/20 0.40
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5785017 0.82 HTR2A (0.49) KMT2AHTR2A
SCHEMBL5786290 0.81 KMT2A (0.42) KMT2AHTR2AHIF1AEPAS1
SCHEMBL5783751 0.81 HTR2A (0.40) KMT2AHTR2AHIF1AEPAS1
SCHEMBL5787801 0.78 KDM4E (0.41) KMT2AHTR2AHIF1AEPAS1
SCHEMBL5783836 0.77 KMT2A (0.42) KMT2AHTR2AHIF1AEPAS1
SCHEMBL28496894 0.76 KMT2A (0.39) KMT2AHTR2A
SCHEMBL4819091 0.76 HTR2A (0.41) HTR2A
Bromide SCHEMBL5784209 0.76 NPC1 (0.39) KMT2AHIF1AEPAS1
SCHEMBL5304830 0.75 HTR2A (0.46) HTR2A
SCHEMBL5788170 0.74 NPC1 (0.44) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270577-B1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-12-06 EP disclosed
US-6924292-B2 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 US disclosed
EP-1270577-A1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof PDE3B, PDE5A, PDE3A KMT2A 1140/4885HTR2A 4536/4885HIF1A 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.